JDR Vol.6 No.4 pp. 413-420
doi: 10.20965/jdr.2011.p0413


West Nile Virus : Understanding its Past, Present, and Future

Yusuke Sayama*,** and Tetsuya Mizutani*

*Department of Virology I, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011, Japan

**Department of Virology, Tohoku University Graduate School of Medicine, 2-1 Seiryou-machi Aoba-ku, Sendai 980-8575, Japan

February 14, 2011
April 1, 2011
August 1, 2011
West Nile virus, mosquito-borne flavivirus, outbreakes, vaccine development, diagnosis
The West Nile virus (WNV) is a mosquito-borne flavivirus that causes significant morbidity and mortality in birds, horses, and humans. WNV-infection causes clinical symptoms such as WNV fever to fatal meningoencephalitis in humans. The emergence and spread of WNV from North America to South America during the last decade and the recent outbreaks of this disease in both humans and horses in Europe suggest that its epidemiology of infection is evolving. This review will present an overview ofWNV virology, vaccine development, and practical aspects of reducing risk of a possible WNV invasion in Japan.
Cite this article as:
Y. Sayama and T. Mizutani, “West Nile Virus : Understanding its Past, Present, and Future,” J. Disaster Res., Vol.6 No.4, pp. 413-420, 2011.
Data files:
  1. [1] H. T. Smithburn, K. C., A.W. Burke, and J. H. Paul, “A Neurotropic Virus Isolated from the Blood of a Native of Uganda,” Am. J. Trop. Med. Hyg., 20, pp. 471-492, 1940.
  2. [2] H. Bernkopf, S. Levine, and R. Nerson, “Isolation of West Nile virus in Israel,” J. Infect. Dis., 93, pp. 207-218, 1953.
  3. [3] J. L.Melnick, J. R. Paul, J. T. Riordan, V. H. Barnett, N. Goldblum, and E. Zabin, “Isolation from human sera in Egypt of a virus apparently identical to West Nile virus,” Proc. Soc. Exp. Biol. Med., 77, pp. 661-665, 1951.
  4. [4] K. M. Pavri and K. R. Singh, “Isolation of West Nile Virus from Culex Fatigans Mosquitoes from Western India,” Indian. J. Med. Res., 53, pp. 501-505, 1965.
  5. [5] B. Le Guenno, A. Bougermouh, T. Azzam, and R. Bouakaz, “West Nile: a deadly virus?,” Lancet, 348, pp. 1315, 1996.
  6. [6] T. F. Tsai, F. Popovici, C. Cernescu, G. L. Campbell, and N. I. Nedelcu, “West Nile encephalitis epidemic in southeastern Romania,” Lancet, 352, pp. 767-771, 1998.
  7. [7] I. Feki, C.Marrakchi, M. Ben Hmida, F. Belahsen, M. Ben Jemaa, I. Maaloul, F. Kanoun, S. Ben Hamed, and C. Mhiri, “Epidemic West Nile virus encephalitis in Tunisia,” Neuroepidemiology, 24, pp. 1-7, 2005.
  8. [8] D. K. Lvov, A. M. Butenko, V. L. Gromashevsky, A. I. Kovtunov, A. G. Prilipov, R. Kinney, V. A. Aristova, A. F. Dzharkenov, E. I. Samokhvalov, H. M. Savage, M. Y. Shchelkanov, I. V. Galkina, P. G. Deryabin, D. J. Gubler, L. N. Kulikova, S. K. Alkhovsky, T. M. Moskvina, L. V. Zlobina, G. K. Sadykova, A. G. Shatalov, D. N. Lvov, V. E. Usachev, and A. G. Voronina, “West Nile virus and other zoonotic viruses in Russia: examples of emerging-reemerging situations,” Arch. Virol. Suppl., pp. 85-96, 2004.
  9. [9] H. Bin, Z. Grossman, S. Pokamunski, M. Malkinson, L. Weiss, P. Duvdevani, C. Banet, Y. Weisman, E. Annis, D. Gandaku, V. Yahalom, M. Hindyieh, L. Shulman, and E. Mendelson, “West Nile fever in Israel 1999-2000: from geese to humans,” Ann. N Y Acad. Sci., 951, pp. 127-142, 2001.
  10. [10] E. Depoortere, J. Kavle, K. Keus, H. Zeller, S. Murri, and D. Legros, “Outbreak of West Nile virus causing severe neurological involvement in children, Nuba Mountains, Sudan, 2002,” Trop. Med. Int. Health, 9, pp. 730-736, 2004.
  11. [11] E. B. Hayes and D. J. Gubler, “West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States,” Annu. Rev. Med., 57, pp. 181-194, 2006.
  12. [12] V. Deubel, L. Fiette, P. Gounon, M. T. Drouet, H. Khun, M. Huerre, C. Banet, M. Malkinson, and P. Despres, “Variations in biological features of West Nile viruses,” Ann. N Y Acad. Sci., 951, pp. 195-206, 2001.
  13. [13] V. T. Huong, D. Q. Ha, and V. Deubel, “Genetic study of Japanese encephalitis viruses from Vietnam,” Am. J. Trop. Med. Hyg., 49, pp. 538-544, 1993.
  14. [14] T. Mizutani, M. Kobayashi, Y. Eshita, K. Shirato, T. Kimura, Y. Ako, H. Miyoshi, T. Takasaki, I. Kurane, H. Kariwa, T. Umemura, and I. Takashima, “Involvement of the JNK-like protein of the Aedes albopictus mosquito cell line, C6/36, in phagocytosis, endocytosis and infection of West Nile virus,” Insect. Mol. Biol., 12, pp. 491-499, 2003.
  15. [15] A. Sampath and R. Padmanabhan, “Molecular targets for flavivirus drug discovery,” Antiviral Res., 81, pp. 6-15, 2009.
  16. [16] L. R. Petersen and J. T. Roehrig, “West Nile virus: a reemerging global pathogen,” Emerg. Infect. Dis., 7, pp. 611-614, 2001.
  17. [17] D. W. Beasley, L. Li, M. T. Suderman, and A. D. Barrett, “Mouse neuroinvasive phenotype ofWest Nile virus strains varies depending upon virus genotype,” Virology, 296, pp. 17-23, 2002.
  18. [18] F. J. Burt, A. A. Grobbelaar, P. A. Leman, F. S. Anthony, G. V. Gibson, and R. Swanepoel, “Phylogenetic relationships of southern African West Nile virus isolates,” Emerg. Infect. Dis., 8, pp. 820-826, 2002.
  19. [19] T. Bakonyi, Z. Hubalek, I. Rudolf, and N. Nowotny, “Novel flavivirus or new lineage of West Nile virus, central Europe,” Emerg. Infect. Dis., 11, pp. 225-231, 2005.
  20. [20] V. P. Bondre, R. S. Jadi, A. C. Mishra, P. N. Yergolkar, and V. A. Arankalle, “West Nile virus isolates from India: evidence for a distinct genetic lineage,” J. Gen. Virol., 88, pp. 875-884, 2007.
  21. [21] E. E. Manuelidis, “Neuropathology of experimental West Nile virus infection in monkeys,” J. Neuropathol. Exp. Neurol., 15, pp. 448-460, 1956.
  22. [22] F. Mostashari, M. L. Bunning, P. T. Kitsutani, D. A. Singer, D. Nash, M. J. Cooper, N. Katz, K. A. Liljebjelke, B. J. Biggerstaff, A. D. Fine, M. C. Layton, S. M. Mullin, A. J. Johnson, D. A. Martin, E. B. Hayes, and G. L. Campbell, “Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey,” Lancet, 358, pp. 261-264, 2001.
  23. [23] E. B. Hayes, N. Komar, R. S. Nasci, S. P. Montgomery, D. R. O’Leary, and G. L. Campbell, “Epidemiology and transmission dynamics of West Nile virus disease,” Emerg. Infect. Dis., 11, pp. 1167-1173, 2005.
  24. [24] J. J. Sejvar, M. B. Haddad, B. C. Tierney, G. L. Campbell, A. A. Marfin, J. A. Van Gerpen, A. Fleischauer, A. A. Leis, D. S. Stokic, and L. R. Petersen, “Neurologic manifestations and outcome of West Nile virus infection,” JAMA, 290, pp. 511-515, 2003.
  25. [25] D. Nash, F. Mostashari, A. Fine, J. Miller, D. O’Leary, K. Murray, A. Huang, A. Rosenberg, A. Greenberg, M. Sherman, S.Wong, and M. Layton, “The outbreak of West Nile virus infection in the New York City area in 1999,” N. Engl. J. Med., 344, pp. 1807-1814, 2001.
  26. [26] M. Y. Chowers, R. Lang, F. Nassar, D. Ben-David, M. Giladi, E. Rubinshtein, A. Itzhaki, J. Mishal, Y. Siegman-Igra, R. Kitzes, N. Pick, Z. Landau, D. Wolf, H. Bin, E. Mendelson, S. D. Pitlik, and M.Weinberger, “Clinical characteristics of the West Nile fever outbreak, Israel, 2000,” Emerg. Infect. Dis., 7, pp. 675-678, 2001.
  27. [27] D. S. Asnis, R. Conetta, A. A. Teixeira, G. Waldman, and B. A. Sampson, “TheWest Nile Virus outbreak of 1999 in New York: the Flushing Hospital experience,” Clin. Infect. Dis., 30, pp. 413-418, 2000.
  28. [28] E. Ceausu, S. Erscoiu, P. Calistru, D. Ispas, O. Dorobat, M. Homos, C. Barbulescu, I. Cojocaru, C. V. Simion, C. Cristea, C. Oprea, C. Dumitrescu, D. Duiculescu, I. Marcu, C. Mociornita, T. Stoicev, I. Zolotusca, C. Calomfirescu, R. Rusu, R. Hodrea, S. Geamai, and L. Paun, “Clinical manifestations in the West Nile virus outbreak,” Rom. J. Virol., 48, pp. 3-11, 1997.
  29. [29] L. E. Jeha, C. A. Sila, R. J. Lederman, R. A. Prayson, C. M. Isada, and S.M. Gordon, “West Nile virus infection: a new acute paralytic illness,” Neurology, 61, pp. 55-59, 2003.
  30. [30] C. Pepperell, N. Rau, S. Krajden, R. Kern, A. Humar, B. Mederski, A. Simor, D. E. Low, A. McGeer, T. Mazzulli, J. Burton, C. Jaigobin, M. Fearon, H. Artsob, M. A. Drebot, W. Halliday, and J. Brunton, “West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario,” CMAJ, 168, pp. 1399-1405, 2003.
  31. [31] J. J. Sejvar, A. V. Bode, A. A. Marfin, G. L. Campbell, D. Ewing, M. Mazowiecki, P. V. Pavot, J. Schmitt, J. Pape, B. J. Biggerstaff, and L. R. Petersen, “West Nile virus-associated flaccid paralysis,” Emerg. Infect. Dis., 11, pp. 1021-1027, 2005.
  32. [32] N. Gadoth, S.Weitzman, and E. E. Lehmann, “Acute anterior myelitis complicating West Nile fever,” Arch. Neurol., 36, pp. 172-173, 1979.
  33. [33] D. Kumar, G. V. Prasad, J. Zaltzman, G. A. Levy, and A. Humar, “Community-acquired West Nile virus infection in solid-organ transplant recipients,” Transplantation, 77, pp. 399-402, 2004.
  34. [34] D. R. O’Leary, A. A. Marfin, S. P. Montgomery, A. M. Kipp, J. A. Lehman, B. J. Biggerstaff, V. L. Elko, P. D. Collins, J. E. Jones, and G. L. Campbell, “The epidemic of West Nile virus in the United States, 2002,” Vector Borne Zoonotic Dis., 4, pp. 61-70, 2004.
  35. [35] V. V. Pogodina, M. P. Frolova, G. V. Malenko, G. I. Fokina, G. V. Koreshkova, L. L. Kiseleva, N. G. Bochkova, and N. M. Ralph, “Study on West Nile virus persistence in monkeys,” Arch. Virol., 75, pp. 71-86, 1983.
  36. [36] T.Wang, T. Town, L. Alexopoulou, J. F. Anderson, E. Fikrig, and R. A. Flavell, “Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis,” Nat. Med., 10, pp. 1366-1373, 2004.
  37. [37] K. Shirato, T. Kimura, T. Mizutani, H. Kariwa, and I. Takashima, “Different chemokine expression in lethal and non-lethal murine West Nile virus infection,” J. Med. Virol., 74, pp. 507-513, 2004.
  38. [38] Z. Hubalek and J. Halouzka, “West Nile fever – a reemerging mosquito-borne viral disease in Europe,” Emerg. Infect. Dis., 5, pp. 643-650, 1999.
  39. [39] Z. Hubalek, “European experience with theWest Nile virus ecology and epidemiology: could it be relevant for the New World?,” Viral. Immunol., 13, pp. 415-426, 2000.
  40. [40] M. Malkinson, C. Banet, Y. Weisman, S. Pokamunski, R. King, M. T. Drouet, and V. Deubel, “Introduction of West Nile virus in the Middle East by migrating white storks,” Emerg. Infect. Dis., 8, pp. 392-397, 2002.
  41. [41] O. Komar, M. B. Robbins, K. Klenk, B. J. Blitvich, N. L. Marlenee, K. L. Burkhalter, D. J. Gubler, G. Gonzalvez, C. J. Pena, A. T. Peterson, and N. Komar, “West Nile virus transmission in resident birds, Dominican Republic,” Emerg. Infect. Dis., 9, pp. 1299-1302, 2003.
  42. [42] N. Komar, “West Nile virus: epidemiology and ecology in North America,” Adv. Virus Res., 61, pp. 185-234, 2003.
  43. [43] M. S. Godsey, Jr., M. S. Blackmore, N. A. Panella, K. Burkhalter, K. Gottfried, L. A. Halsey, R. Rutledge, S. A. Langevin, R. Gates, K. M. Lamonte, A. Lambert, R. S. Lanciotti, C. G. Blackmore, T. Loyless, L. Stark, R. Oliveri, L. Conti, and N. Komar, “West Nile virus epizootiology in the southeastern United States, 2001,” Vector Borne Zoonotic Dis., 5, pp. 82-89, 2005.
  44. [44] G. L. Campbell, C. S. Ceianu, and H. M. Savage, “Epidemic West Nile encephalitis in Romania: waiting for history to repeat itself,” Ann. N Y Acad. Sci., 951, pp. 94-101, 2001.
  45. [45] C. S. Ceianu, A. Ungureanu, G. Nicolescu, C. Cernescu, L. Nitescu, G. Tardei, A. Petrescu, D. Pitigoi, D. Martin, V. Ciulacu-Purcarea, A. Vladimirescu, and H. M. Savage, “West nile virus surveillance in Romania: 1997-2000,” Viral. Immunol., 14, pp. 251-262, 2001.
  46. [46] X. Y. Jia, T. Briese, I. Jordan, A. Rambaut, H. C. Chi, J. S. Mackenzie, R. A. Hall, J. Scherret, and W. I. Lipkin, “Genetic analysis of West Nile New York 1999 encephalitis virus,” Lancet, 354, pp. 1971-1972, 1999.
  47. [47] R. S. Lanciotti, J. T. Roehrig, V. Deubel, J. Smith, M. Parker, K. Steele, B. Crise, K. E. Volpe, M. B. Crabtree, J. H. Scherret, R. A. Hall, J. S. MacKenzie, C. B. Cropp, B. Panigrahy, E. Ostlund, B. Schmitt, M. Malkinson, C. Banet, J. Weissman, N. Komar, H. M. Savage, W. Stone, T. McNamara, and D. J. Gubler, “Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States,” Science, 286, pp. 2333-2337, 1999.
  48. [48] G. L. Hamer, U. D. Kitron, J. D. Brawn, S. R. Loss, M. O. Ruiz, T. L. Goldberg, and E. D.Walker, “Culex pipiens (Diptera: Culicidae): a bridge vector ofWest Nile virus to humans,” J.Med. Entomol., 45, pp. 125-128, 2008.
  49. [49] B. P. Granwehr, K. M. Lillibridge, S. Higgs, P. W. Mason, J. F. Aronson, G. A. Campbell, and A. D. Barrett, “West Nile virus: where are we now?,” Lancet. Infect. Dis., 4, pp. 547-556, 2004.
  50. [50] A. A. Marfin, L. R. Petersen, M. Eidson, J. Miller, J. Hadler, C. Farello, B. Werner, G. L. Campbell, M. Layton, P. Smith, E. Bresnitz, M. Cartter, J. Scaletta, G. Obiri, M. Bunning, R. C. Craven, J. T. Roehrig, K. G. Julian, S. R. Hinten, and D. J. Gubler, “Widespread West Nile virus activity, eastern United States, 2000,” Emerg. Infect. Dis., 7, pp. 730-735, 2001.
  51. [51] G. Dauphin and S. Zientara, “West Nile virus: recent trends in diagnosis and vaccine development,” Vaccine, 25, pp. 5563-5576, 2007.
  52. [52] B. J. Beaty, C. H. Calisher, and R. E. Shope, “Diagnostic procedures for viral, rickettsial, and chlamydial infections,” American Public Health Association, 7th ed, pp. 1995.
  53. [53] B. J. Blitvich, N. L. Marlenee, R. A. Hall, C. H. Calisher, R. A. Bowen, J. T. Roehrig, N. Komar, S. A. Langevin, and B. J. Beaty, “Epitope-blocking enzyme-linked immunosorbent assays for the detection of serum antibodies to west nile virus in multiple avian species,” J. Clin. Microbiol., 41, pp. 1041-1047, 2003.
  54. [54] G. Tardei, S. Ruta, V. Chitu, C. Rossi, T. F. Tsai, and C. Cernescu, “Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile Virus infection,” J. Clin. Microbiol., 38, pp. 2232-2239, 2000.
  55. [55] D. A. Martin, B. J. Biggerstaff, B. Allen, A. J. Johnson, R. S. Lanciotti, and J. T. Roehrig, “Use of immunoglobulin m cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States,” Clin. Diagn. Lab. Immunol., 9, pp. 544-549, 2002.
  56. [56] J. T. Roehrig, D. Nash, B. Maldin, A. Labowitz, D. A. Martin, R. S. Lanciotti, and G. L. Campbell, “Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases,” Emerg. Infect. Dis., 9, pp. 376-379, 2003.
  57. [57] R. S. Lanciotti, A. J. Kerst, R. S. Nasci, M. S. Godsey, C. J. Mitchell, H.M. Savage, N. Komar, N. A. Panella, B. C. Allen, K. E. Volpe, B. S. Davis, and J. T. Roehrig, “Rapid detection of west nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-PCR assay,” J. Clin. Microbiol., 38, pp. 4066-4071, 2000.
  58. [58] K. Shirato, H. Miyoshi, H. Kariwa, and I. Takashima, “Detection of West Nile virus and Japanese encephalitis virus using real-time PCR with a probe common to both viruses,” J. Virol. Methods., 126, pp. 119-125, 2005.
  59. [59] K. Shirato, T. Mizutani, H. Kariwa, and I. Takashima, “Discrimination ofWest Nile virus and Japanese encephalitis virus strains using RT-PCR RFLP analysis,” Microbiol. Immunol., 47, pp. 439-445, 2003.
  60. [60] P. Y. Shi, E. B. Kauffman, P. Ren, A. Felton, J. H. Tai, A. P. Dupuis, 2nd, S. A. Jones, K. A. Ngo, D. C. Nicholas, J. Maffei, G. D. Ebel, K. A. Bernard, and L. D. Kramer, “High-throughput detection of West Nile virus RNA,” J. Clin. Microbiol., 39, pp. 1264-1271, 2001.
  61. [61] A. R. Hunt, R. A. Hall, A. J. Kerst, R. S. Nasci, H. M. Savage, N. A. Panella, K. L. Gottfried, K. L. Burkhalter, and J. T. Roehrig, “Detection of West Nile virus antigen in mosquitoes and avian tissues by a monoclonal antibody-based capture enzyme immunoassay,” J. Clin. Microbiol., 40, pp. 2023-2030, 2002.
  62. [62] K. L. Burkhalter, R. Lindsay, R. Anderson, A. Dibernardo, W. Fong, and R. S. Nasci, “Evaluation of commercial assays for detecting West Nile virus antigen,” J. Am. Mosq. Control Assoc., 22, pp. 64-69, 2006.
  63. [63] K. A. Padgett, B. Cahoon-Young, R. Carney, L. Woods, D. Read, S. Husted, and V. Kramer, “Field and laboratory evaluation of diagnostic assays for detecting West Nile virus in oropharyngeal swabs from California wild birds,” Vector Borne Zoonotic Dis., 6, pp. 183-191, 2006.
  64. [64] J. Macdonald, J. Tonry, R. A. Hall, B. Williams, G. Palacios, M. S. Ashok, O. Jabado, D. Clark, R. B. Tesh, T. Briese, and W. I. Lipkin, “NS1 protein secretion during the acute phase of West Nile virus infection,” J. Virol., 79, pp. 13924-13933, 2005.
  65. [65] C. Cantile, F. Del Piero, G. Di Guardo, and M. Arispici, “Pathologic and immunohistochemical findings in naturally occuring West Nile virus infection in horses,” Vet. Pathol., 38, pp. 414-421, 2001.
  66. [66] P. Leyssen, E. De Clercq, and J. Neyts, “Molecular strategies to inhibit the replication of RNA viruses,” Antiviral Res., 78, pp. 9-25, 2008.
  67. [67] J. M. Minke, L. Siger, K. Karaca, L. Austgen, P. Gordy, R. Bowen, R. W. Renshaw, S. Loosmore, J. C. Audonnet, and B. Nordgren, “Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge,” Arch. Virol. Suppl., pp. 221-230, 2004.
  68. [68] L. H. Gould and E. Fikrig, “West Nile virus: a growing concern?,” J. Clin. Invest., 113, pp. 1102-1107, 2004.
  69. [69] T. Ng, D. Hathaway, N. Jennings, D. Champ, Y. W. Chiang, and H. J. Chu, “Equine vaccine for West Nile virus,” Dev. Biol. (Basel), 114, pp. 221-227, 2003.
  70. [70] I. Samina, M. Havenga, W. Koudstaal, Y. Khinich, M. Koldijk, M. Malkinson, M. Simanov, S. Perl, L. Gijsbers, G. J. Weverling, F. Uytdehaag, and J. Goudsmit, “Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine,” Vaccine, 25, pp. 8338-8345, 2007.
  71. [71] L. Siger, R. A. Bowen, K. Karaca, M. J. Murray, P. W. Gordy, S. M. Loosmore, J. C. Audonnet, R. M. Nordgren, and J. M. Minke, “Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses,” Am. J. Vet. Res., 65, pp. 1459-1462, 2004.
  72. [72] T. P. Monath, J. Liu, N. Kanesa-Thasan, G. A. Myers, R. Nichols, A. Deary, K. McCarthy, C. Johnson, T. Ermak, S. Shin, J. Arroyo, F. Guirakhoo, J. S. Kennedy, F. A. Ennis, S. Green, and P. Bedford, “A live, attenuated recombinant West Nile virus vaccine,” Proc. Natl. Acad. Sci. U.S.A., 103, pp. 6694-6699, 2006.
  73. [73] B. S. Davis, G. J. Chang, B. Cropp, J. T. Roehrig, D. A. Martin, C. J. Mitchell, R. Bowen, and M. L. Bunning, “West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays,” J. Virol., 75, pp. 4040-4047, 2001.
  74. [74] M. K. Goverdhan, A. B. Kulkarni, A. K. Gupta, C. D. Tupe, and J. J. Rodrigues, “Two-way cross-protection between West Nile and Japanese encephalitis viruses in bonnet macaques,” Acta. Virol., 36, pp. 277-283, 1992.
  75. [75] T. Takasaki, S. Yabe, R. Nerome, M. Ito, K. Yamada, and I. Kurane, “Partial protective effect of inactivated Japanese encephalitis vaccine on lethal West Nile virus infection in mice,” Vaccine, 21, pp. 4514-4518, 2003.
  76. [76] G. Yamshchikov, V. Borisevich, C. W. Kwok, R. Nistler, J. Kohlmeier, A. Seregin, E. Chaporgina, S. Benedict, and V. Yamshchikov, “The suitability of yellow fever and Japanese encephalitis vaccines for immunization against West Nile virus,” Vaccine, 23, pp. 4785-4792, 2005.
  77. [77] G. Posadas-Herrera, S. Inoue, I. Fuke, Y. Muraki, C. A. Mapua, A. H. Khan, C. Parquet Mdel, S. Manabe, O. Tanishita, T. Ishikawa, F. F. Natividad, Y. Okuno, F. Hasebe, and K. Morita, “Development and evaluation of a formalin-inactivated West Nile Virus vaccine (WN-VAX) for a human vaccine candidate,” Vaccine, 28, pp. 7939-7946, 2010.

*This site is desgined based on HTML5 and CSS3 for modern browsers, e.g. Chrome, Firefox, Safari, Edge, Opera.

Last updated on May. 19, 2024